Ependymal Tumors: Overview of the Recent World Health Organization Histopathologic and Genetic Updates with an Imaging Characteristic

References

1. 1.↵
   1. Ostrom QT,
   2. Patil N,
   3. Cioffi G, et al

   . CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol 2020;22:iv1–iv96 doi:10.1093/neuonc/noaa200 pmid:33123732

   CrossRefPubMed
2. 2.↵
   1. Jünger ST,
   2. Timmermann B,
   3. Pietsch T

   . Pediatric ependymoma: an overview of a complex disease. Childs Nerv Syst 2021;37:2451–63 doi:10.1007/s00381-021-05207-7 pmid:34008056

   CrossRefPubMed
3. 3.↵
   1. Achey RL,
   2. Vo S,
   3. Cioffi G, et al

   . Ependymoma, NOS and anaplastic ependymoma incidence and survival in the United States varies widely by patient and clinical characteristics, 2000-2016. Neurooncol Pract 2020;7:549–58 doi:10.1093/nop/npaa023 pmid:33014396

   CrossRefPubMed
4. 4.↵
   1. Elsamadicy AA,
   2. Koo AB,
   3. David WB, et al

   . Comparison of epidemiology, treatments, and outcomes in pediatric versus adult ependymoma. Neurooncol Adv 2020;2:vdaa019 doi:10.1093/noajnl/vdaa019 pmid:32642681

   CrossRefPubMed
5. 5.↵
   1. Pajtler KW,
   2. Witt H,
   3. Sill M, et al

   . Molecular classification of ependymal tumors across all CNS compartments, histopathological Grades, and age groups. Cancer Cell 2015;27:728–43 doi:10.1016/j.ccell.2015.04.002 pmid:25965575

   CrossRefPubMed
6. 6.↵
   1. Ellison DW,
   2. Aldape KD,
   3. Capper D, et al

   . cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol 2020;30:863–66 doi:10.1111/bpa.12866 pmid:32502305

   CrossRefPubMed
7. 7.↵
   1. Louis DN,
   2. Perry A,
   3. Wesseling P, et al

   . The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

   CrossRefPubMed
8. 8.↵
   1. McNamara C,
   2. Mankad K,
   3. Thust S, et al

   . 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist. Neuroradiology 2022;64:1919–50 doi:10.1007/s00234-022-03008-6 pmid:35869291

   CrossRefPubMed
9. 9.↵
   1. Kresbach C,
   2. Neyazi S,
   3. Schüller U

   . Updates in the classification of ependymal neoplasms: the 2021 WHO classification and beyond. Brain Pathol 2022;32:e13068 doi:10.1111/bpa.13068 pmid:35307892

   CrossRefPubMed
10. 10.↵
    1. Ghasemi DR,
    2. Sill M,
    3. Okonechnikov K, et al

    . MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathol 2019;138:1075–89 doi:10.1007/s00401-019-02056-2 pmid:31414211

    CrossRefPubMed
11. 11.↵
    1. Mu W,
    2. Dahmoush H

    . Classification and neuroimaging of ependymal tumors. Front Pediatr 2023;11:1181211 doi:10.3389/fped.2023.1181211 pmid:37287627

    CrossRefPubMed
12. 12.↵
    1. Leclerc T,
    2. Levy R,
    3. Tauziède-Espariat A, et al

    . Imaging features to distinguish posterior fossa ependymoma subgroups. Eur Radiology 2024;34:1534–44 doi:10.1007/s00330-023-10182-5 pmid:37658900

    CrossRefPubMed
13. 13.↵
    1. Andreiuolo F,
    2. Varlet P,
    3. Tauziède-Espariat A, et al

    . Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. Brain Pathol 2019;29:205–16 doi:10.1111/bpa.12659 pmid:30246434

    CrossRefPubMed
14. 14.↵
    1. Gamboa NT,
    2. Karsy M,
    3. Gamboa JT, et al

    . Preoperative and intraoperative perfusion magnetic resonance imaging in a RELA fusion-positive anaplastic ependymoma: A case report. Surg Neurol Int 2018;9:144 doi:10.4103/sni.sni_116_18 pmid:30105138

    CrossRefPubMed
15. 15.↵
    1. Cheng D,
    2. Zhuo Z,
    3. Du J, et al

    . A fully automated deep-learning model for predicting the molecular subtypes of posterior fossa ependymomas using T2-weighted images. Clin Cancer Res 2024;30:150–58 doi:10.1158/1078-0432.CCR-23-1461 pmid:37916978

    CrossRefPubMed
16. 16.↵
    1. Osborn AG,
    2. Louis DN,
    3. Poussaint TY, et al

    . The 2021 World Health Organization Classification of Tumors of the Central Nervous System: what neuroradiologists need to know. AJNR Am J Neuroradiol 2022;43:928–37 doi:10.3174/ajnr.A7462 pmid:35710121

    Abstract/FREE Full Text
17. 17.↵
    1. Tauziède-Espariat A,
    2. Siegfried A,
    3. Nicaise Y, et al

    . Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions. Acta Neuropathol Commun 2021;9:135 doi:10.1186/s40478-021-01238-y pmid:34389065

    CrossRefPubMed
18. 18.↵
    1. Parker M,
    2. Mohankumar KM,
    3. Punchihewa C, et al

    . C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 2014;506:451–55 doi:10.1038/nature13109 pmid:24553141

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Nowak J,
    2. Jünger ST,
    3. Huflage H, et al

    . MRI phenotype of RELA-fused pediatric supratentorial ependymoma. Clin Neuroradiol 2019;29:595–604 doi:10.1007/s00062-018-0704-2 pmid:30027327

    CrossRefPubMed
20. 20.↵
    1. Lillard JC,
    2. Venable GT,
    3. Khan NR, et al

    . Pediatric supratentorial ependymoma: surgical, clinical, and molecular analysis. Neurosurgery 2019;85:41–49 doi:10.1093/neuros/nyy239 pmid:29917116

    CrossRefPubMed
21. 21.↵
    1. Malgulwar PB,
    2. Nambirajan A,
    3. Pathak P, et al

    . C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin. J Neurooncol 2018;138:29–39 doi:10.1007/s11060-018-2767-y pmid:29354850

    CrossRefPubMed
22. 22.↵
    1. Yuh EL,
    2. Barkovich AJ,
    3. Gupta N

    . Imaging of ependymomas: MRI and CT. Childs Nerv Syst 2009;25:1203–13 doi:10.1007/s00381-009-0878-7 pmid:19360419

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Gessi M,
    2. Giagnacovo M,
    3. Modena P, et al

    . Role of immunohistochemistry in the identification of supratentorial C11ORF95-RELA fused ependymoma in routine neuropathology. Am J Surg Pathol 2019;43:56–63 doi:10.1097/PAS.0000000000000979 pmid:29266023

    CrossRefPubMed
24. 24.↵
    1. Upadhyaya SA,
    2. Robinson GW,
    3. Onar-Thomas A, et al

    . Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. Neuro Oncol 2019;21:1319–30 doi:10.1093/neuonc/noz069 pmid:30976811

    CrossRefPubMed
25. 25.↵
    1. Pagès M,
    2. Pajtler KW,
    3. Puget S, et al

    . Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. Brain Pathol 2019;29:325–35 doi:10.1111/bpa.12664 pmid:30325077

    CrossRefPubMed
26. 26.↵
    1. Jünger ST,
    2. Andreiuolo F,
    3. Mynarek M, et al

    . CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. Acta Neuropathol 2020;140:405–07 doi:10.1007/s00401-020-02169-z pmid:32514758

    CrossRefPubMed
27. 27.↵
    1. Rudà R,
    2. Bruno F,
    3. Pellerino A, et al

    . Ependymoma: evaluation and management updates. Curr Oncol Rep 2022;24:985–93 doi:10.1007/s11912-022-01260-w pmid:35384591

    CrossRefPubMed
28. 28.↵
    1. Donovan LK,
    2. Delaidelli A,
    3. Joseph SK, et al

    . Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med 2020;26:720–31 doi:10.1038/s41591-020-0827-2 pmid:32341580

    CrossRefPubMed
29. 29.↵
    1. Zaytseva M,
    2. Papusha L,
    3. Novichkova G, et al

    . Molecular stratification of childhood ependymomas as a basis for personalized diagnostics and treatment. Cancers 2021;13:4954 doi:10.3390/cancers13194954

    CrossRefPubMed
30. 30.↵
    1. Tauziède-Espariat A,
    2. Siegfried A,
    3. Nicaise Y, et al

    . A novel YAP1-MAML2 fusion in an adult supra-tentorial ependymoma, YAP1-fused. Brain Tumor Pathol 2022;39:240–42 doi:10.1007/s10014-022-00439-0 pmid:35598201

    CrossRefPubMed
31. 31.↵
    1. Merchant TE,
    2. Bendel AE,
    3. Sabin ND, et al

    . Conformal radiation therapy for pediatric ependymoma, chemotherapy for incompletely resected ependymoma, and observation for completely resected, supratentorial ependymoma. J Clin Oncol 2019;37:974–83 doi:10.1200/JCO.18.01765 pmid:30811284

    CrossRefPubMed
32. 32.↵
    1. Massimino M,
    2. Barretta F,
    3. Modena P, et al

    . Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up. Neuro Oncol 2021;23:848–57 doi:10.1093/neuonc/noaa257 pmid:33135735

    CrossRefPubMed
33. 33.↵
    1. Cavalli FMG,
    2. Hübner JM,
    3. Sharma T, et al

    . Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol 2018;136:227–37 doi:10.1007/s00401-018-1888-x pmid:30019219

    CrossRefPubMed
34. 34.↵
    1. Nambirajan A,
    2. Sharma A,
    3. Rajeshwari M, et al

    . EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations. Brain Tumor Pathol 2021;38:30–40 doi:10.1007/s10014-020-00385-9 pmid:33130928

    CrossRefPubMed
35. 35.↵
    1. Pun M,
    2. Pratt D,
    3. Nano PR, et al

    . Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways. Acta Neuropathol Commun 2023;11:25 doi:10.1186/s40478-023-01514-z pmid:36759899

    CrossRefPubMed
36. 36.↵
    1. Panwalkar P,
    2. Clark J,
    3. Ramaswamy V, et al

    . Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 2017;134:705–14 doi:10.1007/s00401-017-1752-4 pmid:28733933

    CrossRefPubMed
37. 37.↵
    1. Zhao F,
    2. Wu T,
    3. Wang LM, et al

    . Survival and prognostic factors of adult intracranial ependymoma: a single-institutional analysis of 236 patients. Am J Surg Pathol 2021;45:979–87 doi:10.1097/PAS.0000000000001669 pmid:33739788

    CrossRefPubMed
38. 38.↵
    1. Pajtler KW,
    2. Wen J,
    3. Sill M, et al

    . Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol 2018;136:211–26 doi:10.1007/s00401-018-1877-0 pmid:29909548

    CrossRefPubMed
39. 39.↵
    1. Witt H,
    2. Gramatzki D,
    3. Hentschel B

    , German Glioma Network, et al. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. Neuro Oncol 2018;20:1616–24 doi:10.1093/neuonc/noy118 pmid:30053291

    CrossRefPubMed
40. 40.↵
    1. Zhang M,
    2. Wang E,
    3. Yecies D, et al

    . Radiomic signatures of posterior fossa ependymoma: molecular subgroups and risk profiles. Neuro Oncol 2022;24:986–94 doi:10.1093/neuonc/noab272 pmid:34850171

    CrossRefPubMed
41. 41.↵
    1. Sabin ND,
    2. Hwang SN,
    3. Klimo P, Jr., et al

    . Anatomic neuroimaging characteristics of posterior fossa type A ependymoma subgroups. AJNR Am J Neuroradiol 2021;42:2245–50 doi:10.3174/ajnr.A7322 pmid:34674998

    Abstract/FREE Full Text
42. 42.↵
    1. Yonezawa U,
    2. Karlowee V,
    3. Amatya VJ, et al

    . Radiology profile as a potential instrument to differentiate between posterior fossa ependymoma (PF-EPN) group A and B. World Neurosurg 2020;140:e320–e327 doi:10.1016/j.wneu.2020.05.063 pmid:32428725

    CrossRefPubMed
43. 43.↵
    1. Bayliss J,
    2. Mukherjee P,
    3. Lu C, et al

    . Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Sci Transl Med 2016;8:366ra161 doi:10.1126/scitranslmed.aah6904 pmid:27881822

    Abstract/FREE Full Text
44. 44.↵
    1. Han J,
    2. Yu M,
    3. Bai Y, et al

    . Elevated CXorf67 expression in PFA ependymomas suppresses DNA repair and sensitizes to PARP inhibitors. Cancer Cell 2020;38:844–56.e847 doi:10.1016/j.ccell.2020.10.009 pmid:33186520

    CrossRefPubMed
45. 45.↵
    1. Ramaswamy V,
    2. Hielscher T,
    3. Mack SC, et al

    . Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis. J Clin Oncol 2016;34:2468–77 doi:10.1200/JCO.2015.65.7825 pmid:27269943

    Abstract/FREE Full Text
46. 46.↵
    1. Jin Y,
    2. Cheng D,
    3. Duan Y, et al

    . “Soap bubble” sign as an imaging marker for posterior fossa ependymoma Group B. Neuroradiology 2023;65:1707–14 doi:10.1007/s00234-023-03231-9 pmid:37837480

    CrossRefPubMed
47. 47.↵
    1. Thompson YY,
    2. Ramaswamy V,
    3. Diamandis P, et al

    . Posterior fossa ependymoma: current insights. Childs Nerv Syst 2015;31:1699–706 doi:10.1007/s00381-015-2823-2 pmid:26351223

    CrossRefPubMed
48. 48.↵
    1. D'Arco F,
    2. Khan F,
    3. Mankad K, et al

    . Differential diagnosis of posterior fossa tumours in children: new insights. Pediatr Radiology 2018;48:1955–63 doi:10.1007/s00247-018-4224-7 pmid:30120502

    CrossRefPubMed
49. 49.↵
    1. Koeller KK,
    2. Rosenblum RS,
    3. Morrison AL

    . Neoplasms of the spinal cord and filum terminale: radiologic-pathologic correlation. Radiographics 2000;20:1721–49 doi:10.1148/radiographics.20.6.g00nv151721 pmid:11112826

    CrossRefPubMedWeb of Science
50. 50.↵
    1. Ostrom QT,
    2. Cioffi G,
    3. Gittleman H, et al

    . CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol 2019;21:v1–v100 doi:10.1093/neuonc/noz150 pmid:31675094

    CrossRefPubMed
51. 51.↵
    1. Kresbach C,
    2. Dorostkar MM,
    3. Suwala AK, et al

    . Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype. Acta Neuropathol 2021;141:971–74 doi:10.1007/s00401-021-02304-4 pmid:33844070

    CrossRefPubMed
52. 52.↵
    1. Plotkin SR,
    2. O'Donnell CC,
    3. Curry WT, et al

    . Spinal ependymomas in neurofibromatosis type 2: a retrospective analysis of 55 patients. J Neurosurg Spine 2011;14:543–47 doi:10.3171/2010.11.SPINE10350 pmid:21294614

    CrossRefPubMedWeb of Science
53. 53.↵
    1. Santi M,
    2. Viaene AN,
    3. Hawkins C

    . Ependymal tumors. Pediatr Dev Pathol 2022;25:59–67 doi:10.1177/10935266211018928 pmid:35168420

    CrossRefPubMed
54. 54.↵
    1. Jung JS,
    2. Choi YS,
    3. Ahn SS, et al

    . Differentiation between spinal cord diffuse midline glioma with histone H3 K27M mutation and wild type: comparative magnetic resonance imaging. Neuroradiology 2019;61:313–22 doi:10.1007/s00234-019-02154-8 pmid:30662997

    CrossRefPubMed
55. 55.↵
    1. Benesch M,
    2. Frappaz D,
    3. Massimino M

    . Spinal cord ependymomas in children and adolescents. Childs Nerv Syst 2012;28:2017–28 doi:10.1007/s00381-012-1908-4 pmid:22961356

    CrossRefPubMed
56. 56.↵
    1. Entenmann CJ,
    2. Mišove A,
    3. Holub M, et al

    . Current management in the treatment of intramedullary ependymomas in children. Childs Nerv Syst 2023;39:1183–92 doi:10.1007/s00381-022-05814-y pmid:36574011

    CrossRefPubMed
57. 57.↵
    1. Shatara M,
    2. Schieffer KM,
    3. Klawinski D, et al

    . Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas. Acta Neuropathol Commun 2021;9:192 doi:10.1186/s40478-021-01296-2 pmid:34895332

    CrossRefPubMed
58. 58.↵
    1. Beltran H

    . The N-myc oncogene: maximizing its targets, regulation, and therapeutic potential. Mol Cancer Res 2014;12:815–22 doi:10.1158/1541-7786.MCR-13-0536 pmid:24589438

    Abstract/FREE Full Text
59. 59.↵
    1. Swanson AA,
    2. Raghunathan A,
    3. Jenkins RB, et al

    . Spinal cord ependymomas with MYCN amplification show aggressive clinical behavior. J Neuropathol Exp Neurol 2019;78:791–97 doi:10.1093/jnen/nlz064 pmid:31373367

    CrossRefPubMed
60. 60.↵
    1. Ghasemi DR,
    2. Sill M,
    3. Okonechnikov K, et al

    . EPEN-10. Spinal ependymoma with mycn-amplification – a disease of childhood and young adulthood with dismal prognosis. Neuro-Oncology 2023;25:i28–i29 doi:10.1093/neuonc/noad073.114

    CrossRef
61. 61.↵
    1. Stermann A,
    2. Huebener N,
    3. Seidel D, et al

    . Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice. Cancer Immunol Immunother 2015;64:1215–27 doi:10.1007/s00262-015-1733-1 pmid:26076666

    CrossRefPubMed
62. 62.↵
    1. Koeller KK,
    2. Shih RY

    . Intradural extramedullary spinal neoplasms: radiologic-pathologic correlation. Radiographics 2019;39:468–90 doi:10.1148/rg.2019180200 pmid:30844353

    CrossRefPubMed
63. 63.↵
    1. Weber DC,
    2. Wang Y,
    3. Miller R, et al

    . Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. Neuro Oncol 2015;17:588–95 doi:10.1093/neuonc/nou293 pmid:25301811

    CrossRefPubMed
64. 64.↵
    1. Mastantuoni C,
    2. Tortora F,
    3. Tafuto R, et al

    . Extra-neural metastases of late recurrent myxopapillary ependymoma to left lumbar paravertebral muscles: case report and review of the literature. Brain Sciences 2022;12:12 doi:10.3390/brainsci12091227

    CrossRef
65. 65.↵
    1. Zhang Y-W,
    2. Wang B,
    3. An S-Y, et al

    . Clinical management and prognosis of spinal myxopapillary ependymoma: a single-institution cohort of 72 patients. Eur Spine J 2023;32:2459–67 doi:10.1007/s00586-023-07690-9 pmid:37027035

    CrossRefPubMed
66. 66.↵
    1. Lamzabi I,
    2. Arvanitis LD,
    3. Reddy VB, et al

    . Immunophenotype of myxopapillary ependymomas. Appl Immunohistochem Mol Morphol 2013;21:485–89 doi:10.1097/PAI.0b013e318283980a pmid:23455181

    CrossRefPubMed
67. 67.↵
    1. Bandopadhayay P,
    2. Silvera VM,
    3. Ciarlini P, et al

    . Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol 2016;126:165–74 doi:10.1007/s11060-015-1955-2 pmid:26468139

    CrossRefPubMed
68. 68.↵
    1. Abdallah A,
    2. Emel E,
    3. Gündüz HB, et al

    . Long-term surgical resection outcomes of pediatric myxopapillary ependymoma: experience of two centers and brief literature review. World Neurosurg 2020;136:e245–e261 doi:10.1016/j.wneu.2019.12.128 pmid:31899399

    CrossRefPubMed
69. 69.↵
    1. Smith AB,
    2. Smirniotopoulos JG,
    3. Horkanyne-Szakaly I

    . From the radiologic pathology archives: intraventricular neoplasms: radiologic-pathologic correlation. Radiographics 2013;33:21–43 doi:10.1148/rg.331125192 pmid:23322825

    CrossRefPubMed
70. 70.↵
    1. Nguyen HS,
    2. Doan N,
    3. Gelsomino M, et al

    . Intracranial subependymoma: a SEER analysis 2004-2013. World Neurosurg 2017;101:599–605 doi:10.1016/j.wneu.2017.02.019 pmid:28232153

    CrossRefPubMed
71. 71.↵
    1. Kweh BTS,
    2. Rosenfeld JV,
    3. Hunn M, et al

    . Tumor characteristics and surgical outcomes of intracranial subependymomas: a systematic review and meta-analysis. J Neurosurg 2022;136:736–48 doi:10.3171/2021.2.JNS204052 pmid:34416731

    CrossRefPubMed
72. 72.↵
    1. Bi Z,
    2. Ren X,
    3. Zhang J, et al

    . Clinical, radiological, and pathological features in 43 cases of intracranial subependymoma. J Neurosurg 2015;122:49–60 doi:10.3171/2014.9.JNS14155 pmid:25361493

    CrossRefPubMed
73. 73.↵
    1. Minh ND,
    2. Hung ND,
    3. Giang DT, et al

    . Diagnosis of symmetric bilateral lateral ventricular subependymomas: a case report. Exp Ther Med 2022;24:503 doi:10.3892/etm.2022.11429 pmid:35837028

    CrossRefPubMed
74. 74.↵
    1. Moinuddin FM,
    2. Ikbar Khairunnisa N,
    3. Hirano H, et al

    . Bilateral lateral ventricular subependymoma with extensive multiplicity presenting with hemorrhage. Neuroradiol J 2018;31:27–31 doi:10.1177/1971400917718843 pmid:28696174

    CrossRefPubMed
75. 75.↵
    1. Yuh WT,
    2. Chung CK,
    3. Park S-H, et al

    . Spinal cord subependymoma surgery: a multi-institutional experience. J Korean Neurosurg Soc 2018;61:233–42 doi:10.3340/jkns.2017.0405.001 pmid:29526067

    CrossRefPubMed
76. 76.↵
    1. Varma A,
    2. Giraldi D,
    3. Mills S, et al

    . Surgical management and long-term outcome of intracranial subependymoma. Acta Neurochir (Wien) 2018;160:1793–99 doi:10.1007/s00701-018-3570-4 pmid:29915887

    CrossRefPubMed